Latanoprost Pharmabide (Latanoprost)

Latanoprost acts as a prostaglandin F (FP) receptor agonist in the eye. Activation of these receptors remodels the extracellular matrix of the ciliary muscle, enhancing uveoscleral outflow of aqueous humor, which reduces intraocular pressure and mitigates glaucoma progression.

The prescribed dose is determined by the treating ophthalmologist. Typically, one drop is instilled into the affected eye(s) once daily, usually in the evening, but the exact regimen should follow the prescriber’s instructions.

Safety data for Latanoprost in pregnancy and lactation are limited. The product is classified as having an unknown pregnancy category, so clinicians must weigh potential benefits against possible risks before prescribing to pregnant or nursing women.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Latanoprost belongs to the prostaglandin analog class, which generally offers once‑daily dosing and strong intraocular pressure reduction. Compared with beta‑blocker eye drops such as timolol, prostaglandin analogs often have a more favorable dosing schedule and comparable efficacy, though side‑effect profiles differ.

Store the ophthalmic solution at room temperature, away from direct sunlight. Keep the bottle tightly closed in its original packaging to protect from moisture and light. Do not freeze the product, and discard any solution that appears discolored or contains particles.

Instill one drop of Latanoprost Pharmabide into the conjunctival sac of the prescribed eye(s) once daily, preferably in the evening. Avoid touching the tip of the bottle to the eye or any other surface to maintain sterility.

Serious adverse events, though rare, include severe allergic reactions, uveitis, macular edema, paradoxical increase in intraocular pressure, and corneal edema. Patients should seek immediate medical attention if they experience sudden vision loss, eye pain, redness, or swelling.

Latanoprost Pharmabide should be avoided in individuals with known hypersensitivity to latanoprost or any component of the formulation, active ocular infections, or severe inflammation of the eye. Caution is also advised for patients with a history of uveitis or corneal disease.